As of today (2024-04-18), Y-mAbs Therapeutics's share price is $15.00. Y-mAbs Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $2.25. Hence, Y-mAbs Therapeutics's Price to Tangible Book Ratio of today is 6.66.
The historical rank and industry rank for Y-mAbs Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
YMAB'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.01 Med: 4.46 Max: 19.03
Current: 6.67
During the past 8 years, Y-mAbs Therapeutics's highest Price to Tangible Book Ratio was 19.03. The lowest was 2.01. And the median was 4.46.
YMAB's Price-to-Tangible-Book is ranked worse than 81.03% of 1223
companies
in the Biotechnology industry
Industry Median: 2.7
vs YMAB: 6.67
A closely related ratio is called PB Ratio. As of today, Y-mAbs Therapeutics's share price is $15.00. Y-mAbs Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.31. Hence, Y-mAbs Therapeutics's P/B Ratio of today is 6.49.
Y-mAbs Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Y-mAbs Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Y-mAbs Therapeutics Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
6.24
19.03
3.97
2.01
3.03
Y-mAbs Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
2.01
2.09
2.91
2.44
3.03
Competitive Comparison
For the Biotechnology subindustry, Y-mAbs Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y-mAbs Therapeutics Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Y-mAbs Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YMAB has been successfully added to your 